

# ForPatients

by Roche

Hepatocellular Carcinoma (HCC)

## A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

**Trial Status**  
Recruiting

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT06096779 ML44719

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis.

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT06096779 ML44719**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---